Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Simple and cost-effective cancer diagnosis in liquid biopsy through native tRNA sequencing

Project description

tRNA biomarkers for cancer diagnosis

In cancer cells, dysregulation of transfer RNAs (tRNAs) and their modifications influences the translation of oncogenic proteins. Despite this link, tRNAs remain underutilised as diagnostic or prognostic markers due to the absence of simple, cost-effective quantification methods. The EU-funded tRNADiagnostics project addresses this knowledge gap with the innovative Nano-tRNAseq by using native tRNA nanopore sequencing to accurately measure tRNA abundances and modifications at a fraction of traditional sequencing costs. This method, combined with deep learning algorithms for rapid signal classification, shows promise in distinguishing cancerous samples and identifying their tissue of origin. The project aims to validate this technology for liquid biopsies, paving the way for clinical applications and potential commercialisation.

Objective

Transfer RNAs (tRNAs) are abundant, heavily-modified small non-coding RNAs that play a pivotal role in decoding genetic information, determining which transcripts are highly and poorly translated at a given moment. Dysregulation of tRNA abundances and tRNA modifications is a well-known feature in cancer cells, leading to enhanced translation of specific oncogenic proteins. Despite the well-established association between tRNA dysregulation and cancer progression and malignancy, tRNA abundances and their modifications are still not being used as diagnostic or prognostic markers for cancer detection or progression, mainly due to the lack of a simple, unbiased and cost-effective method to quantify tRNA abundances and their modifications. Our laboratory has recently established Nano-tRNAseq, a pioneering method that can accurately quantify both tRNA abundances and tRNA modifications using native tRNA nanopore sequencing, for a fraction of the cost of next-generation sequencing-based approaches. By employing a proprietary Nano-tRNAseq nanopore library preparation protocol coupled with deep learning algorithms that will rapidly classify the nanopore current signals, here we aim to establish a method that exploits tRNAs as novel biomarkers through the use of third generation sequencing technologies. We have initial evidence of how our approach can separate cancer from non-cancer samples and possibly be used to identify the tissue of origin. In this project, we will fully validate our technological platform for the differential analysis of low-input RNA amounts in liquid biopsy samples. We will initially apply our method in the cancer arena, expandable to many other indications, following the advice of key stakeholders contacted so far, with the goal of laying the basis for the transfer of our technology to the marketplace, including through the creation of a new start-up company.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-POC

See all projects funded under this call

Host institution

FUNDACIO CENTRE DE REGULACIO GENOMICA
Net EU contribution
€ 150 000,00
Address
CARRER DOCTOR AIGUADER 88
08003 Barcelona
Spain
Region
Este Cataluña Barcelona
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (1)